# Antibiotic Prophylaxis in Rhinoplasty

> **NCT04194216** · PHASE3 · ENROLLING_BY_INVITATION · sponsor: **Stanford University** · enrollment: 864 (estimated)

## Conditions studied

- Nasal Obstruction
- Nasal Surgical Procedures

## Interventions

- **DRUG:** Intra-operative single intravenous(iv) dose of "cephalexin" 2 g or "clindamycin" 900 mg.
- **DRUG:** Intra-operative single dose (iv) of "cephalexin" 2 g or "clindamycin" 900 mg and postoperative oral dose of "cephalexin" 250mg (every 4 hours) or "clindamycin" 150mg(every 6 hours) for 3 days

## Key facts

- **NCT ID:** NCT04194216
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2020-05-20
- **Primary completion:** 2026-12-20
- **Final completion:** 2027-04-20
- **Target enrollment:** 864 (ESTIMATED)
- **Last updated:** 2026-04-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04194216

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04194216, "Antibiotic Prophylaxis in Rhinoplasty". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04194216. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*